Skip to main content
Premium Trial:

Request an Annual Quote

Paul Cusenza


Paul Cusenza has become Perlegen’s vice president of alliance management, a new position. He joins the company from Capital One Financial, where he was managing director of value-added alliances and vice president for marketing and analysis. Prior to that, he was a vice president and partner at Mercer Management Consulting. Cusenza also consulted Perlegen prior to its spin-off from Affymetrix. He holds an MBA from Harvard Business School and a BS in mechanical engineering from the University of Michigan.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.